Results showed in this article have strong implications for developing anti-ZIKV vaccines and therapeutic mAbs.

4th February 2020 • comment

Data from this study suggest that immunity against the Zika virus may not last as long as previously thought, which could affect the chances of future outbreaks.

28th January 2020 • comment

Researchers developed a ZEDIII-based ELISA that can discriminate between past or current DENV and ZIKV infections, allowing the detection of a serological scar from other flaviviruses. This could be used to confirm exposure of pregnant women or to follow the spread of an endemic disease.

20th September 2019 • comment

Letter to the Editor

3rd September 2019 • comment

In this review, the authors summarize the results of the evidence to date and elaborate on other possible detrimental effects of cross-reactive flavivirus antibodies, both for ZIKV infection and the risk of ZIKV-related congenital anomalies, DENV infection, and dengue hemorrhagic fever.

18th April 2019 • comment

In Suriname, 770 participants were recruited from 1 urban area and 2 rural villages in the tropical rainforest in order to conduct a ZIKV serosurvey. Researchers found that 35.1% of the participants had neutralizing antibodies against ZIKV. In 1 remote village in the rainforest, 24.5% of the participants had neutralizing antibodies against ZIKV, suggesting that ZIKV was widely spread across the country.

12th February 2019 • comment

In 2015–2016 in the Recife Metropolitan Region, the authors of this study detected the tail end of a Zika epidemic, which was displaced by a chikungunya epidemic. Few dengue cases were identified despite a high number of official dengue notifications in the area during this period. This study shows here important epidemiological features of these cases.

6th November 2017 • comment